Cargando…

Deletion of the Vaccinia Virus Gene A46R, Encoding for an Inhibitor of TLR Signalling, Is an Effective Approach to Enhance the Immunogenicity in Mice of the HIV/AIDS Vaccine Candidate NYVAC-C

Viruses have developed strategies to counteract signalling through Toll-like receptors (TLRs) that are involved in the detection of viruses and induction of proinflammatory cytokines and IFNs. Vaccinia virus (VACV) encodes A46 protein which disrupts TLR signalling by interfering with TLR: adaptor in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perdiguero, Beatriz, Gómez, Carmen Elena, Di Pilato, Mauro, Sorzano, Carlos Oscar S., Delaloye, Julie, Roger, Thierry, Calandra, Thierry, Pantaleo, Giuseppe, Esteban, Mariano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3775734/ https://www.ncbi.nlm.nih.gov/pubmed/24069354 http://dx.doi.org/10.1371/journal.pone.0074831

Ejemplares similares

Immune Modulation of NYVAC-Based HIV Vaccines by Combined Deletion of Viral Genes that Act on Several Signalling Pathways
por: Gómez, Carmen Elena, et al.
Publicado: (2017)

Deletion of the Viral Anti-Apoptotic Gene F1L in the HIV/AIDS Vaccine Candidate MVA-C Enhances Immune Responses against HIV-1 Antigens
por: Perdiguero, Beatriz, et al.
Publicado: (2012)

Innate Immune Sensing of Modified Vaccinia Virus Ankara (MVA) Is Mediated by TLR2-TLR6, MDA-5 and the NALP3 Inflammasome
por: Delaloye, Julie, et al.
Publicado: (2009)

Improved NYVAC-Based Vaccine Vectors
por: Kibler, Karen V., et al.
Publicado: (2011)

Insertion of Vaccinia Virus C7L Host Range Gene into NYVAC-B Genome Potentiates Immune Responses against HIV-1 Antigens
por: Nájera, José Luis, et al.
Publicado: (2010)

Correction for Kibler et al., “Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC”
por: Kibler, Karen V., et al.
Publicado: (2019)

Deletion of Vaccinia Virus A40R Gene Improves the Immunogenicity of the HIV-1 Vaccine Candidate MVA-B
por: Pérez, Patricia, et al.
Publicado: (2020)

A Candidate HIV/AIDS Vaccine (MVA-B) Lacking Vaccinia Virus Gene C6L Enhances Memory HIV-1-Specific T-Cell Responses
por: García-Arriaza, Juan, et al.
Publicado: (2011)

Early and Long-Term HIV-1 Immunogenicity Induced in Macaques by the Combined Administration of DNA, NYVAC and Env Protein-Based Vaccine Candidates: The AUP512 Study
por: Perdiguero, Beatriz, et al.
Publicado: (2022)

Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses
por: Perdiguero, Beatriz, et al.
Publicado: (2019)

Involvement of the Cellular Phosphatase DUSP1 in Vaccinia Virus Infection
por: Cáceres, Ana, et al.
Publicado: (2013)

Improved Innate and Adaptive Immunostimulation by Genetically Modified HIV-1 Protein Expressing NYVAC Vectors
por: Quakkelaar, Esther D., et al.
Publicado: (2011)

Removal of the C6 Vaccinia Virus Interferon-β Inhibitor in the Hepatitis C Vaccine Candidate MVA-HCV Elicited in Mice High Immunogenicity in Spite of Reduced Host Gene Expression
por: Q. Marín, María, et al.
Publicado: (2018)

Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways
por: García-Arriaza, Juan, et al.
Publicado: (2013)

Immunogenic Profiling in Mice of a HIV/AIDS Vaccine Candidate (MVA-B) Expressing Four HIV-1 Antigens and Potentiation by Specific Gene Deletions
por: García-Arriaza, Juan, et al.
Publicado: (2010)

Systems Analysis of MVA-C Induced Immune Response Reveals Its Significance as a Vaccine Candidate against HIV/AIDS of Clade C
por: Gómez, Carmen Elena, et al.
Publicado: (2012)

Correction: Systems Analysis of MVA-C Induced Immune Response Reveals Its Significance as a Vaccine Candidate against HIV/AIDS of Clade C
por: Gómez, Carmen Elena, et al.
Publicado: (2012)

Correction: Systems Analysis of MVA-C Induced Immune Response Reveals Its Significance as a Vaccine Candidate against HIV/AIDS of Clade C
por: Gómez, Carmen Elena, et al.
Publicado: (2012)

Vaccinia virus strain NYVAC induces substantially lower and qualitatively different human antibody responses compared with strains Lister and Dryvax
por: Midgley, Claire M., et al.
Publicado: (2008)

Invasive candidiasis as a cause of sepsis in the critically ill patient
por: Delaloye, Julie, et al.
Publicado: (2014)

rAd5/NYVAC-B is superior to NYVAC-B/rAd5 and is dependent on rAd5 dose for neutralizing antibody responses against HIV-1
por: Montefiori, DC, et al.
Publicado: (2012)

P17-07. Insertion of a vaccinia virus host range (hr) gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens
por: Najera, JL, et al.
Publicado: (2009)

Effect of the ati Gene Deletion on the Pathogenicity and Immunogenicity of the Vaccinia Virus
por: Yakubitskiy, S. N., et al.
Publicado: (2023)

A Human Multi-Epitope Recombinant Vaccinia Virus as a Universal T Cell Vaccine Candidate against Influenza Virus
por: Goodman, Alan G., et al.
Publicado: (2011)

Increased attenuation but decreased immunogenicity by deletion of multiple vaccinia virus immunomodulators
por: Sumner, Rebecca P., et al.
Publicado: (2016)

A Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV Immunogen
por: Vijayan, Aneesh, et al.
Publicado: (2015)

Immunogenicity and efficacy of a novel multi-patch SARS-CoV-2/COVID-19 vaccine candidate
por: Perdiguero, Beatriz, et al.
Publicado: (2023)

Effect of the Deletion of Genes Encoding Proteins of the Extracellular Virion Form of Vaccinia Virus on Vaccine Immunogenicity and Protective Effectiveness in the Mouse Model
por: Meseda, Clement A., et al.
Publicado: (2013)

rAd5 prime/NYVAC-B boost regimen is superior to NYVAC-B prime/rAd5 boost regimen for both response rates and magnitude of CD4 and CD8 T-cell responses
por: Bart, P, et al.
Publicado: (2012)

Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial
por: Pantaleo, Giuseppe, et al.
Publicado: (2019)

An MVA Vector Expressing HIV-1 Envelope under the Control of a Potent Vaccinia Virus Promoter as a Promising Strategy in HIV/AIDS Vaccine Design
por: Pérez, Patricia, et al.
Publicado: (2019)

OA021-01. Construction and characterization of replication competent attenuated NYVAC-based vectors as potential HIV vaccines
por: Jacobs, B, et al.
Publicado: (2009)

Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C
por: Gómez, C, et al.
Publicado: (2012)

Enhancing the Immunogenicity of Vaccinia Virus
por: Shchelkunov, Sergei N., et al.
Publicado: (2022)

An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses
por: Harari, Alexandre, et al.
Publicado: (2008)

Role of TLR1, TLR2 and TLR6 in the modulation of intestinal inflammation and Candida albicans elimination
por: Choteau, Laura, et al.
Publicado: (2017)

Modified Vaccinia Virus Ankara as a Viral Vector for Vaccine Candidates against Chikungunya Virus
por: García-Arriaza, Juan, et al.
Publicado: (2021)

The Combination of an mRNA Immunogen, a TLR7 Agonist and a PD1 Blocking Agent Enhances In-Vitro HIV T-Cell Immune Responses
por: Usero, Lorena, et al.
Publicado: (2023)

A Novel MVA-Based HIV Vaccine Candidate (MVA-gp145-GPN) Co-Expressing Clade C Membrane-Bound Trimeric gp145 Env and Gag-Induced Virus-Like Particles (VLPs) Triggered Broad and Multifunctional HIV-1-Specific T Cell and Antibody Responses
por: Perdiguero, Beatriz, et al.
Publicado: (2019)

Genes that Control Vaccinia Virus Immunogenicity
por: Shchelkunov, S. N., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9480qq3057kqsbjm2u0bfp18pj